US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,327.58

-9.1315-0.68%

Number of Gainers:5

Number of Losers:15

Number of Flat:- -

PE:- -

High:1,343.21

Open:1,342.69

Low:1,326.57

Close:1,336.71

Loading ...

Corvus Pharmaceuticals Up Over 26%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk

Wall Street Set to Open Higher Friday as Investors Calmed by Trade Talks

MT Newswires Live

AstraZeneca's Imfinzi Combination Therapy Boosts Disease-Free Survival in Bladder Cancer Trial

MT Newswires Live

Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib

BRIEF-J&J's Skin Disease Drug Meets Main Goal In Late-Stage Study

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stoke Therapeutics (STOK), Novavax (NVAX) and McKesson (MCK)

US Equity Futures Higher as Trump Considers 80% China Tariffs

MT Newswires Live

Ocugen Inc - Reports $0.05 Net Loss per Share for Q1 2025

THOMSON REUTERS

Ocugen Q1 Operating Expenses USD 15.982 Million

THOMSON REUTERS

Press Release: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

Flu, COVID-19 vaccines now mandatory for Singapore Haj pilgrims

Vir Biotechnology Inc - Hbsag Loss Achieved in 17% and 21% of Participants

THOMSON REUTERS

Vir Biotechnology Inc - Reiterates Cash Runway Guidance Into Mid-2027

THOMSON REUTERS

Vir Biotechnology Inc - Tobevibart and Elebsiran Show Consistent Safety Profile

THOMSON REUTERS

Vir Biotechnology Inc - to Streamline March Phase 2 Study

THOMSON REUTERS

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the March Study

THOMSON REUTERS

Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket

MT Newswires Live

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Vir Biotechnology (VIR) and Liquidia Technologies (LQDA)

Health Care Down on Cyclical Bias -- Health Care Roundup

BRIEF-Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal For Contractors - SEC Filing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4568/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1327.5806,"timestamp":1746820799999,"preClose":1336.712,"halted":0,"volume":113582454,"delay":0,"changeRate":-0.006831,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-9.13147,"latestTime":"05-09 16:00:00 EDT","open":1342.69,"high":1343.2052,"low":1326.5701,"amount":4653162209.902576,"amplitude":0.012445,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.565313,"peRate":21.186942,"turnoverRate":0.007317,"increases":5,"decrements":15,"flats":0,"marketCap":1093969830401.5,"floatMarketCap":1075897192963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1343.2052,"amplitude":0.012445,"preClose":1336.712,"low":1326.5701,"pbRate":"3.565313","latestPrice":1327.5806,"volume":113582454,"delay":0,"open":1342.69,"prevYearClose":1274.8187,"prevWeekClose":1375.2667,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1375.2667,"twentyDayClose":1281.7616,"sixtyDayClose":1380.7908,"secType":"PLATE","market":"US","turnoverRate":0.007317,"peRate":21.186942,"marketCap":1093969830401.5,"floatMarketCap":1075897192963,"timestamp":1746820799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":5,"down":15,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534434962","title":"Corvus Pharmaceuticals Up Over 26%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2534434962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534434962?lang=en_us&edition=fundamental","pubTime":"2025-05-09 23:30","pubTimestamp":1746804600,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals, Inc.  is currently at $4.24, up $0.89 or 26.57%. --Would be highest close since March 24, 2025, when it closed at $4.25. --On pace for largest percent increase since May 17, 2023, when it rose 36.71%. --Currently up two consecutive days; up 32.5% over this period. --Down 80.16% from its all-time closing high of $21.37 on March 27, 2017. --Up 103.85% from 52 weeks ago , when it closed at $2.08. --Traded as high as $4.38; highest intraday level since March 25, 2025, when it hit $4.38. --Up 30.74% at today's intraday high; largest intraday percent increase since May 17, 2023, when it rose as much as 38.82%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVS","BK4568","BK4139"],"gpt_icon":0},{"id":"2534482172","title":"Wall Street Set to Open Higher Friday as Investors Calmed by Trade Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2534482172","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534482172?lang=en_us&edition=fundamental","pubTime":"2025-05-09 21:17","pubTimestamp":1746796639,"startTime":"0","endTime":"0","summary":"US stocks look set to open higher in Friday's trading session as investors were encouraged by remarks by US President Donald Trump indicating that several trade deals were in the making.The Dow Jones ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VEEE","IOVA","BK4588","BK4539","FLWS","CRVS","LU1852331112.SGD","BK4125","BK4548","BK4585","PINS","ZKIN","BK4006","BK4200","LU1861215975.USD","BK4077","BK4122","LU2317271919.USD","WOLF","BBGI","IE00B894F039.SGD","GOGO","LU1861220033.SGD","BK4551","BK4508","IE00BMPRXN33.USD","BK4534","IE00BZ9MQY76.HKD","ISBC","BK4190","BK4139","BK4132","BK4141","LU0348723411.USD","BK4211","IE00B19Z9P08.USD","IE00BMPRXR70.SGD","IE00B19Z9Z06.USD","BK4568","LU0056508442.USD"],"gpt_icon":1},{"id":"2534489725","title":"AstraZeneca's Imfinzi Combination Therapy Boosts Disease-Free Survival in Bladder Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2534489725","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534489725?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:40","pubTimestamp":1746794408,"startTime":"0","endTime":"0","summary":"AstraZeneca  said Friday that its late-stage trial of its therapy, Imfinzi, when combined with standard BCG induction and maintenance therapy, showed significantly improved disease-free survival in patients with high-risk non-muscle-invasive bladder cancer.The company said the trial was not statistically powered to formally test overall survival but a descriptive analysis demonstrated no detriment.The drugmaker said the therapy did not raise new safety concerns and did not compromise patients' ability to complete BCG induction and maintenance therapy.A second experimental arm evaluating Imfinzi combined with BCG induction-only therapy compared to BCG induction and maintenance therapy alone failed to meet the endpoint of disease-free survival, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","LU2456880835.USD","BK4588","LU0320765992.SGD","BK4585","LU1829250122.USD","LU2417539215.USD","BK4568","BK4007","LU2236285917.USD","LU2462157665.USD","AZN","LU0889565916.HKD"],"gpt_icon":0},{"id":"2534894514","title":"Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2534894514","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534894514?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:35","pubTimestamp":1746794100,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib.Shares were trading around $4.33. The stock is down 38% on the year.The clinical-stage biopharmaceutical company said Thursday that new data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis demonstrated a favorable safety and efficacy profile.Overall, three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints, said Corvus.The company said it's on track to initiate a Phase 2 trial before the end of the year.Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","CRVS"],"gpt_icon":0},{"id":"2534486755","title":"BRIEF-J&J's Skin Disease Drug Meets Main Goal In Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2534486755","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534486755?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:24","pubTimestamp":1746793464,"startTime":"0","endTime":"0","summary":"BRIEF-J&J's Skin Disease Drug Meets Main Goal In Late-Stage StudyMay 9 (Reuters) - Johnson & Johnson JNJ.N:ICOTROKINRA RESULTS SHOW SIGNIFICANT SKIN CLEARANCE IN PATIENTS WITH DIFFICULT-TO-TREAT SCALP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA2S26C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU1059921491.USD","LU2505996681.GBP","LU2430703178.SGD","IE00B42XCP33.USD","LU1430594728.SGD","SG9999002224.SGD","BK4568","LU0058720904.USD","LU1221951129.SGD","LU0912757837.SGD","BK4534","IE00B19Z3B42.SGD","LU1066053197.SGD","IE00BSNM7G36.USD","JNJ","LU0234570918.USD","LU1196500208.SGD","IE00BFXG1179.USD","LU1929549753.HKD","LU2112291526.USD","IE00BBT3K403.USD","LU0234572021.USD","IE0002141913.USD","SG9999002232.USD","LU2347655156.SGD","LU2602419157.SGD","IE00BDGV0183.EUR","LU0345770993.USD","LU1280957306.USD","LU1894683264.USD","LU0203345920.USD","LU0203347892.USD","IE00BVYPNW00.USD","IE00BGHQF631.EUR","LU0345769631.USD","LU0098860793.USD","IE0009355771.USD","LU1162221912.USD","LU1935042991.SGD","LU2089984988.USD","LU1914381329.SGD","BK4533","LU1244550577.SGD","LU2468319806.SGD","LU0795875169.SGD","LU0466842654.USD","LU1267930813.SGD","IE00B3PB1722.GBP","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2534486095","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Stoke Therapeutics (STOK), Novavax (NVAX) and McKesson (MCK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2534486095","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534486095?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:20","pubTimestamp":1746793248,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Stoke Therapeutics (STOK – Research Report), Novav...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-stoke-therapeutics-stok-novavax-nvax-and-mckesson-mck?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-stoke-therapeutics-stok-novavax-nvax-and-mckesson-mck?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1934455863.HKD","LU1037948897.HKD","LU0203345920.USD","LU1061106388.HKD","LU0314106906.USD","BK4137","BK4547","LU1934455277.USD","LU0861579265.USD","LU0251142724.SGD","BK4588","LU0965509283.SGD","LU1366192091.USD","BK4139","HCSG","LU0251131958.USD","LU1934455194.USD","LU1983260115.SGD","LU0122379950.USD","LU1814569148.SGD","BK4585","LU0048573561.USD","LU1023059063.AUD","LU2324357040.USD","LU0742534661.SGD","LU0965509010.AUD","LU0965509101.SGD","LU1037948541.HKD","LU2089984988.USD","NVAX","LU2468319806.SGD","LU2112291526.USD","LU0868494708.USD","BK4568","LU1585245621.USD","LU0868494617.USD","BK4533","LU1506573853.SGD","BK4175","STOK","LU0942090050.USD","MCK","LU1430594728.SGD","LU0965508806.USD","LU0203347892.USD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2534866054","title":"US Equity Futures Higher as Trump Considers 80% China Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2534866054","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534866054?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:14","pubTimestamp":1746792858,"startTime":"0","endTime":"0","summary":"US stock futures were higher in premarket activity Friday after US President Donald Trump posted on Truth Social that an \"80% tariff on China seems right!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IOVA","DJX","BK4539","BK4568","BK4006",".DJI","BK4190","USAW.SI","MNQmain","USJW.SI","MYMmain","EQR",".IXIC","BK4215","NVIW.SI","NQmain","BBGI","TSYW.SI","UDOW","CRVS","DDM","VEEE","TQQQ","BK4139","QID","BK4588",".SPX","SDOW","DXD","BK4125","ZKIN","BK4585","QLD","PSQ","SQQQ","DOG","JBIO"],"gpt_icon":1},{"id":"2534654485","title":"Ocugen Inc - Reports $0.05 Net Loss per Share for Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2534654485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534654485?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:01","pubTimestamp":1746792067,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA4JXJ7R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4568","BK4139","OCGN"],"gpt_icon":0},{"id":"2534856124","title":"Ocugen Q1 Operating Expenses USD 15.982 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2534856124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534856124?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:01","pubTimestamp":1746792067,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nPLX460F52:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4563","OCGN","BK4139"],"gpt_icon":0},{"id":"2534892104","title":"Press Release: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534892104","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534892104?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:50","pubTimestamp":1746787800,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast today at 8:30 a.m. EDT. CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update.\"We had another solid quarter, with an increase in revenues from selling goods compared to the prior year quarter,\" said Dror Bashan, Protalix's President and Chief Executive Officer. \"Given the promising results obtained in 2024 from our first-in-human study of our gout candidate, PRX-115, we are focused on building on the momentum and working toward initiating a phase II clinical trial in patients with gout later this year. At the same time, we continued to evaluate additional pipeline candidates for potential further develo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003800.SGD","BK4232","BK4585","LU0122379950.USD","LU0306807586.USD","LU0868494617.USD","LU0985481810.HKD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","SG9999001176.USD","SG9999011175.SGD","BK4568","LU0321505439.SGD","LU0225284248.USD","BK4588","03160","PLX","SGXZ57979304.SGD","PK","BK4218","IE00BLSP4452.SGD","LU0170899867.USD","LU1057294990.SGD","R","SG9999002232.USD","BK4099","LU1894683348.USD","BK4599","BK4022","LU1066053197.SGD","LU1883839398.USD","BK4581","LU1066051498.USD","SG9999002224.SGD","LU0225771236.USD","BK4534","SG9999013999.USD","TM","SG9999001176.SGD","LU1023059063.AUD","LU1894683264.USD","BK4604","BK4555","IE00BBT3K403.USD","LU0321505868.SGD","IE00BLSP4239.USD","ACR","LU0289739699.SGD","IE000M9KFDE8.USD"],"gpt_icon":1},{"id":"2534363432","title":"Flu, COVID-19 vaccines now mandatory for Singapore Haj pilgrims","url":"https://stock-news.laohu8.com/highlight/detail?id=2534363432","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534363432?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:08","pubTimestamp":1746785280,"startTime":"0","endTime":"0","summary":"Before this, only the meningococcal vaccination was required of Haj pilgrims from Singapore.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--E1On_pQs--/c_crop,h_900,w_1600,x_0,y_130/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2023-11:afp_watermark_14112023,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/05/09/haj_pilgrimage_2024.jpg?itok=ZuzJaSNM","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--E1On_pQs--/c_crop,h_900,w_1600,x_0,y_130/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2023-11:afp_watermark_14112023,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/05/09/haj_pilgrimage_2024.jpg?itok=ZuzJaSNM"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/singapore-haj-pilgrims-vaccination-requirements-2025-influenza-covid-19-5119466","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BNTX","BK4154","BK4551","SG9999014013.SGD","BK4535","BK4532","SG9999014021.USD","MOH","SG9999014039.USD","BK4585","BK4139","BK4568","SG9999014005.SGD","BK4588","BK4548"],"gpt_icon":0},{"id":"2534717772","title":"Vir Biotechnology Inc - Hbsag Loss Achieved in 17% and 21% of Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2534717772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534717772?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:00","pubTimestamp":1746784800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA8RKYFF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","VIR","BK4568","BK4585","BK4139"],"gpt_icon":0},{"id":"2534517772","title":"Vir Biotechnology Inc - Reiterates Cash Runway Guidance Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2534517772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534517772?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:00","pubTimestamp":1746784800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA8RKYFF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","VIR","BK4568","BK4585"],"gpt_icon":0},{"id":"2534177729","title":"Vir Biotechnology Inc - Tobevibart and Elebsiran Show Consistent Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177729?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:00","pubTimestamp":1746784800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA8RKYFF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","BK4568","BK4585","VIR"],"gpt_icon":0},{"id":"2534177717","title":"Vir Biotechnology Inc - to Streamline March Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177717?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:00","pubTimestamp":1746784800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA8RKYFF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIR","BK4568","BK4535","BK4139","BK4585"],"gpt_icon":0},{"id":"2534177619","title":"Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the March Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177619?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:00","pubTimestamp":1746784800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA8RKYFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4568","BK4535","BK4139","VIR"],"gpt_icon":0},{"id":"2534179498","title":"Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2534179498","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534179498?lang=en_us&edition=fundamental","pubTime":"2025-05-09 17:20","pubTimestamp":1746782446,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals  said late Thursday that new interim data from a phase 1 clinical trial of soquelitinib to treat moderate to severe atopic dermatitis showed a \"favorable\" safety and efficacy profile.The company found \"earlier and deeper responses\" in group 3, which received 200 milligrams twice a day, compared with groups 1 and 2, which received 100 mg twice daily and 200 mg once daily.Corvus said that all three groups showed \"significant responses\" in the soquelitinib treatment groups, compared with placebo for clinically significant endpoints.Atopic dermatitis is a skin condition characterized by dry, itchy, and inflamed skin.Shares of the company were up 37% in recent premarket activity Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","CRVS","BK4139"],"gpt_icon":0},{"id":"2534114923","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Vir Biotechnology (VIR) and Liquidia Technologies (LQDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2534114923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534114923?lang=en_us&edition=fundamental","pubTime":"2025-05-09 10:30","pubTimestamp":1746757825,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arcellx Inc (ACLX – Research Report), Vir Biotechnology (VIR – Re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-arcellx-inc-aclx-vir-biotechnology-vir-and-liquidia-technologies-lqda?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-arcellx-inc-aclx-vir-biotechnology-vir-and-liquidia-technologies-lqda?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ACLX","BK4137","VIR","BK4585","HCSG","BK4139","BK4568","LQDA","BK4535"],"gpt_icon":0},{"id":"2534193016","title":"Health Care Down on Cyclical Bias -- Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2534193016","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534193016?lang=en_us&edition=fundamental","pubTime":"2025-05-09 06:27","pubTimestamp":1746743220,"startTime":"0","endTime":"0","summary":"Health-care companies fell as traders rotated into cyclical sectors.Kenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, and named Kellanova Chief Financial Officer Amit Banati as its financial chief.Shares of troubled Covid-19 vaccine developer Novavax rose sharply after it logged a significant profit, boosted by payments related to the termination of two purchase contracts.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4588","BK4568","BK4585","BK4139","NVAX"],"gpt_icon":0},{"id":"2534934711","title":"BRIEF-Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal For Contractors - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2534934711","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534934711?lang=en_us&edition=fundamental","pubTime":"2025-05-09 06:25","pubTimestamp":1746743103,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal For Contractors - SEC FilingGilead Sciences Inc GILD.O:GILEAD SCIENCES INC - STOCKHOLDERS REJECT DEI PRACTICES RISK REPORT PROPOSAL FOR CONTRACTORS - SEC FILINGGILEAD SCIENCES INC - STOCKHOLDERS REJECT INDEPENDENT BOARD CHAIR POLICY PROPOSAL - SEC FILINGSource text: [ID:n0000882095-25-000015]Further company coverage: GILD.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG4BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU1674673691.USD","BK4585","LU1585245621.USD","LU1571399168.USD","LU1778281490.HKD","IE00B19Z3B42.SGD","BK4566","IE00B3T34201.USD","IE00B7SZLL34.SGD","BK4588","BK4532","LU2468319806.SGD","LU1430594728.SGD","LU2089984988.USD","LU1839511570.USD","LU0109394709.USD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","BK4568","LU1674673428.USD","IE0002270589.USD","BK4550","LU2087621335.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","BK4583","LU1066053197.SGD","LU0289739699.SGD","GILD","BK4139","BK4578","LU0320765992.SGD","LU1066051498.USD","LU0234570918.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":1,"totalSize":328,"code":"91000000","status":"200"}]}}